Illumina launches BioInsight Platform for genomic data analysis

Wed, 14 Oct 2026 09:16:22 -0400

Illumina, Inc. (NASDAQ: ILMN) has launched the BioInsight Platform, which the company describes as its first unified software environment for genomic and multiomic data analysis, according to a company statement released Oct. 14, 2026.

The platform consolidates Illumina's analysis applications, AI tools, and curated data resources under a single sign-on. It includes DRAGEN v4.6, an updated version of the company's secondary analysis software that adds deployment options across supported cloud and standard CPU environments. Previous versions had more limited deployment flexibility.

The platform also features the BioInsight AI Lab, which applies multiomic data and AI for variant effect prediction and prioritization, and

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

Wed, 14 Oct 2026 09:15:00 -0400

The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight

Included in the new platform, latest DRAGEN update expands access to Illumina's award-winning secondary analysis across supported cloud and standard computing environment

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

Wed, 14 Oct 2026 09:15:00 -0400

The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight

Included in the new platform, latest DRAGEN update expands access to Illumina's award-winning secondary analysis across supported cloud and standard computing environment

Illumina establishes $1B commercial paper program

Tue, 13 Oct 2026 16:50:50 -0400

Illumina, Inc. (NASDAQ: ILMN) established an unsecured commercial paper program on October 8, 2026, under which the company may issue short-term, unsecured commercial paper notes with an aggregate principal amount not to exceed $1.0 billion outstanding at any time.

The notes will mature within 397 days from the date of issue and will be issued either at a discount from par or at par with fixed or floating interest rates. The company said net proceeds are expected to be used for general corporate purposes.

Three commercial paper dealers will act under the program, with a national bank serving as issuing and paying

Illumina establishes $1B commercial paper program

Tue, 13 Oct 2026 16:50:50 -0400

Three commercial paper dealers will act under the program, with a national bank serving as issuing and paying

Form 8-K ILLUMINA, INC. For: Oct 13

Tue, 13 Oct 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20261013/27181709.html

Illumina (ILMN) PT Raised to $270 at TD Cowen

Tue, 13 Oct 2026 09:30:47 -0400

TD Cowen analyst Dan Brennan raised the price target on Illumina (NASDAQ: ILMN) to $270.00 (from $210.00) while maintaining a rating.

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Thu, 08 Oct 2026 16:06:00 -0400

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026.

On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Thu, 08 Oct 2026 16:06:00 -0400

On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host

Illumina launches SpliceAI2 genomic AI model for variant research

Thu, 08 Oct 2026 09:15:36 -0400

Illumina, Inc. (NASDAQ: ILMN) introduced SpliceAI2, a genomic AI model designed to identify disease-relevant splice variants, according to a company press release dated Oct. 8, 2026.

The company said SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models when applied to a rare disease research dataset. The finding is based on analyses of matched DNA and disease phenotype data from Genomics England cohorts.

Analysis of matched whole genome and RNA sequencing data from the NIH's Genotype-Tissue Expression Portal showed that SpliceAI2 improved quantification of splice site usage by 34% compared to the next best model, according to a preprint released

Illumina releases SpliceAI2 to help advance rare disease research

Thu, 08 Oct 2026 09:15:00 -0400

In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models

Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:

Illumina releases SpliceAI2 to help advance rare disease research

Thu, 08 Oct 2026 09:15:00 -0400

In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models

Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:

Illumina (ILMN) PT Raised to $286 at Baird

Thu, 08 Oct 2026 07:23:27 -0400

Baird analyst Catherine Ramsey Schulte raised the price target on Illumina (NASDAQ: ILMN) to $286.00 (from $225.00) while maintaining a Neutral rating.

Form 4 ILLUMINA, INC. For: Oct 05 Filed by: Thaysen Jacob

Wed, 07 Oct 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20261007/27161860.html

Form SCHEDULE 13G ILLUMINA, INC. Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27159977.html

Illumina (ILMN) PT Raised to $200 at Barclays

Wed, 07 Oct 2026 03:50:08 -0400

Barclays analyst Luke Sergott raised the price target on Illumina (NASDAQ: ILMN) to $200.00 (from $160.00) while maintaining a Underweight rating.

Illumina (ILMN) call put ratio 1 call to 5.9 puts with a focus on November 300 puts as share price trends higher

Tue, 06 Oct 2026 09:55:53 -0400

Illumina (NASDAQ: ILMN) 30-day option implied volatility is at 63; compared to its 52-week range of 38 to 73. Call put ratio 1 call to 5.9 puts with a focus on November 300 puts as share price trends higher.

Illumina (ILMN) PT Raised to $310 at RBC Capital

Mon, 05 Oct 2026 08:54:05 -0400

(Updated - October 5, 2026 8:54 AM EDT)

RBC Capital analyst Dan Leonard raised the price target on Illumina (NASDAQ: ILMN) to $310.00 (from $230.00) while maintaining a Outperform rating.

The analyst commented: "We're increasing our price target on Outperform-rated Illumina (ILMN) to $310 from $230. This increase reflects the multiple re-rating of the Illumina ecosystem, due to clinical sales inflection and positive catalysts. Illumina's multiple is also receiving a modest lift from Tools companies being newly recast as AI beneficiaries. While the latter only reflects modestly in our thinking and customer purchasing dynamics create near-term noise, the underlying thesis on Illumina

Illumina (ILMN) PT Raised to $310 at RBC Capital

Mon, 05 Oct 2026 08:54:05 -0400

(Updated - October 5, 2026 8:54 AM EDT)

RBC Capital analyst Dan Leonard raised the price target on Illumina (NASDAQ: ILMN) to $310.00 (from $230.00) while maintaining a Outperform rating.

Form 4 ILLUMINA, INC. For: Sep 30 Filed by: Meister Keith A.

Fri, 02 Oct 2026 20:12:00 -0400

si-local-file:///var/storage/secattach/20261002/27144105.html

Form 4 ILLUMINA, INC. For: Sep 30 Filed by: Ullem Scott B.

Fri, 02 Oct 2026 19:56:00 -0400

si-local-file:///var/storage/secattach/20261002/27144065.html

Illumina (ILMN) PT Raised to $305 at Guggenheim

Thu, 01 Oct 2026 08:48:12 -0400

Guggenheim analyst Subbu Nambi raised the price target on Illumina (NASDAQ: ILMN) to $305.00 (from $226.00) while maintaining a Buy rating.

Illumina (ILMN) PT Raised to $305 at Piper Sandler

Mon, 28 Sep 2026 06:43:59 -0400

Piper Sandler analyst Dave Westenberg raised the price target on Illumina (NASDAQ: ILMN) to $305.00 (from $225.00) while maintaining a Overweight rating.

Form 4 ILLUMINA, INC. For: Sep 08 Filed by: Coletti Julie Ann

Thu, 10 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260910/27049224.html

UBS Resumes Illumina (ILMN) at Buy

Wed, 09 Sep 2026 06:07:31 -0400

UBS analyst Douglas Schenkel resumes coverage on Illumina (NASDAQ: ILMN) with a Buy rating and a price target of $260.00.

For an analyst ratings summary and ratings history on Illumina click here. For more ratings news on Illumina click here.

Shares of Illumina closed at $211.06 yesterday.

StreetInsider.com News Articles

Illumina launches BioInsight Platform for genomic data analysis

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

Illumina establishes $1B commercial paper program

Illumina establishes $1B commercial paper program

Form 8-K ILLUMINA, INC. For: Oct 13

Illumina (ILMN) PT Raised to $270 at TD Cowen

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Illumina launches SpliceAI2 genomic AI model for variant research

Illumina releases SpliceAI2 to help advance rare disease research

Illumina releases SpliceAI2 to help advance rare disease research

Illumina (ILMN) PT Raised to $286 at Baird

Form 4 ILLUMINA, INC. For: Oct 05 Filed by: Thaysen Jacob

Form SCHEDULE 13G ILLUMINA, INC. Filed by: FMR LLC

Illumina (ILMN) PT Raised to $200 at Barclays

Illumina (ILMN) call put ratio 1 call to 5.9 puts with a focus on November 300 puts as share price trends higher

Illumina (ILMN) PT Raised to $310 at RBC Capital

Illumina (ILMN) PT Raised to $310 at RBC Capital

Form 4 ILLUMINA, INC. For: Sep 30 Filed by: Meister Keith A.

Form 4 ILLUMINA, INC. For: Sep 30 Filed by: Ullem Scott B.

Illumina (ILMN) PT Raised to $305 at Guggenheim

Illumina (ILMN) PT Raised to $305 at Piper Sandler

Form 4 ILLUMINA, INC. For: Sep 08 Filed by: Coletti Julie Ann

UBS Resumes Illumina (ILMN) at Buy